Drug Trial Radar · NCT07357675
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Oct 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- EBI Anti Sepsis BVIndustry
- Sponsor type
- Industry
- Collaborators
- CR2O B.V.
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future. This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.
Conditions
- Coronary Artery Disease (CAD)
- Coronary Artery Bypass Graft Surgery(CABG)
Interventions
EA-230 90mg/kg/hourDrug
Intravenous administration of 90mg/kg per hour for 4 hours.
PlaceboDrug
Placebo administered intravenously for 4 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Required postoperative hospital length of stayTime frame: Up to 28 days
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
MAYO clinic
Rochester, Minnesota · Not yet recruiting
UPMC
Pittsburgh, Pennsylvania · Not yet recruiting
UZ Gent
Ghent, Belgium · Recruiting
Medisch Spectrum Twente
Enschede, Netherlands · Recruiting
RadboudUMC
Nijmegen, Netherlands · Recruiting
St Thomas' Hospital
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.